StreetAlpha.app
Home › Stocks › FATE

Fate Therapeutics Inc (FATE)

Healthcare
$1.02
▼ −10.53%
LAST CLOSE · NOV 17

Fate Therapeutics develops off-the-shelf cell immunotherapies made from stem cells, mainly for autoimmune diseases and cancer. It last closed at $1.02 on Nov 17, down 10.53% on the day.

AI Auto Pilots
Is FATE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$4.8M
−33.4% vs a year ago
Net income
−$124.4M
−2619.6% margin
EPS (diluted)
−$1.03
Free cash flow
−$107.0M
−2252.1% margin
Valuation
Market cap
$124.0M
121.6M shares
P/E
–
No P/E while losing money
Price to sales
26.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$43.9M
At Sep 30
Shareholder equity
$133.0M
Shares outstanding
121.6M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $55.8M$55.8MFY2021FY2022: $96.3M$96.3MFY2022FY2023: $63.5M$63.5MFY2023FY2024: $13.6M$13.6MFY2024FY2025: $6.6M$6.6MFY2025

From FATE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated FATE in the past 90 days, not enough for a consensus
Average 12-month target
$3.00
▲ 194.1% upside

Based on 1 analyst who set a price target on FATE in the past 90 days. The average target is $3.00, with a high of $3.00 and a low of $3.00, compared with the last close of $1.02.

Low $3.00Avg $3.00High $3.00
Blue marker: last close $1.02
Highest target$3.00
Average target$3.00
Lowest target$3.00
Latest rating changes
Wells FargoTarget lowered
Nov 6Hold$3.50 → $3
Piper SandlerReiterated
Aug 14Buy$8
Wells FargoMaintained
Aug 14Hold$3.50
WedbushReiterated
Aug 14Buy$7
HC Wainwright & Co.Reiterated
Jun 8Buy$7
DateFirmActionRatingPrice target
Nov 6Wells FargoTarget loweredHold$3.50 → $3
Aug 14Piper SandlerReiteratedBuy$8
Aug 14Wells FargoMaintainedHold$3.50
Aug 14WedbushReiteratedBuy$7
Jun 8HC Wainwright & Co.ReiteratedBuy$7
Loading…

Technical Analysis

FATE · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 80% below its 20 day and 106% below its 50 day average. It is 95% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 19), oversold. The nearest support is the Pivot S1 at $0.98, and the nearest resistance the Pivot at $1.05.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 16.0%/day
Key levels
$3.2352 week high+216.7%
$2.37100 day average+132.4%
$2.15Swing high (Oct 20)+110.8%
$2.1050 day average+105.9%
$1.99200 day average+95.1%
$1.8420 day average+80.4%
$1.10Pivot R1+7.8%
$1.05Pivot+2.9%
$1.02Last close
$0.98Pivot S1−3.9%
$0.9552 week low−6.9%
Indicators
RSI (14)19.20Oversold below 30Oversold
MACD-0.25Below its signal lineBearish
Stochastic3.2Near the bottom of its rangeOversold
ADX (14)25.6Trending down
Williams %R-99.2Oversold below −80, overbought above −20Oversold
CCI (20)-194.3Oversold below −100, overbought above 100Oversold
Rate of change−50.0%Change over 10 sessionsBearish
ATR (14)$0.16Typical daily range, 16.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for FATE

What happened before

See how FATE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow FATE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How FATE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in FATE in the last 90 days.

Loading…

See today’s whale options flow across the market →

FATE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼49 buying vs 79 selling
  • ●Held by funds -0.4 pts
  • ▼Funds holding -14
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding142156−9.0%
In funds' top 10110.0%
Held by funds58.6%59.0%−0.4 pts
New / increased17 / 3231 / 59−45.6%
Reduced / sold out50 / 2935 / 30+21.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See FATE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether FATE is in one of them and how their past FATE trades turned out.

FATE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered FATE in an article yet. Here's the latest on the wider market.

FATE Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Feb 24
Who traded FATE · since 2023
Latest 1 filing
$1K – $15KTraded Jan 31, 2023Filed Feb 24, 2023
PersonTypeAmountTradedFiledDelay
Dan GoldmanD · NYSell$1K – $15KJan 31, 2023Feb 24, 202324 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops off-the-shelf cellular immunotherapies, mainly CAR T-cell and natural killer cell product candidates made from induced pluripotent stem cells. Its current focus is on treating autoimmune diseases such as lupus, along with cancer, and its candidates are being studied in clinical trials for patients with these conditions.

Headquarters
San Diego, CA